Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

Alcon

Status and phase: Terminated; Phase 4

Conditions: Open-angle Glaucoma; Ocular Hypertension

Treatments: Drug: Cosopt; Drug: Travatan; Drug: Placebo (Timolol Vehicle)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00471068

EMD-05-03

Details and patient eligibility

About

To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension

Enrollment: 46 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with open-angle glaucoma or ocular hypertension

Exclusion criteria

• By Age

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

46 participants in 2 patient groups

Travatan

Experimental group

Description:

Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

Treatment:

Drug: Placebo (Timolol Vehicle)

Drug: Travatan

Cosopt

Active Comparator group

Description:

treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

Treatment:

Drug: Cosopt